Radius Health (RDUS) Tops Q4 EPS by 48c, Revenues Beat; Offers FY20 Revenue Guidance Below Consensus
Get Alerts RDUS Hot Sheet
Join SI Premium – FREE
Radius Health (NASDAQ: RDUS) reported Q4 EPS of ($0.29), $0.48 better than the analyst estimate of ($0.77). Revenue for the quarter came in at $55.67 million versus the consensus estimate of $53.29 million.
“I am very pleased that TYMLOS exited 2019 with a December majority share of postmenopausal osteoporosis patients starting on anabolic therapy in the U.S. market. In 2020, we have three critical objectives: continue expanding our market share for TYMLOS, reach anabolic total market share leadership, and complete recruitment in our three pivotal Phase 3 studies,” said Jesper Hoeiland, President and Chief Executive Officer of Radius.
GUIDANCE:
Radius Health sees FY2020 revenue of $220-235 million, versus the consensus of $246.17 million.
For earnings history and earnings-related data on Radius Health (RDUS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Alphabet stock surges 11% to record high on Q1 earnings beat, first-ever dividend
- Amundi surges as on bigger-than-expected profit, record AUM
- T-Mobile posts mixed Q1 top and bottom line, expects more subscribers in 2024
Create E-mail Alert Related Categories
Corporate News, Earnings, Guidance, Management CommentsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!